By John Gruber
Kolide ensures only secure devices can access your cloud apps.
It’s Zero Trust for Okta.
Matt Novak, writing for Gizmodo:
EpiPen, the life-saving allergy product, is now a $1 billion a year business for Mylan, a drug company that’s currently enduring a wave of bad publicity over the extraordinary surge in EpiPen pricing. In 2007, an EpiPen cost about $57. Today that price has skyrocketed to over $600 — all for about $1 worth of injectable medicine.
EpiPen is an emergency medication that’s stabbed into a person experiencing anaphylactic shock, a life-threatening allergic reaction that can be triggered by anything from bee stings to food. I’ve never used an EpiPen, but as someone with a peanut allergy who once made his own trip to the ER after a particularly unfortunate restaurant experience (“these Chinese beans sure are crunchy…”) I can tell you that anaphylactic shock is really no fun.
Mylan is able to do this because they have no competitors in the U.S. Not one. If you need an EpiPen, you’re buying theirs. It’s despicable. Long-time DF readers may know that my son has a severe dairy allergy, so we’ve been buying EpiPens for years. Our insurance covers two per year, but after that we’re buying them out of pocket. We’ve never had to use one, knock on wood, but they expire every year, and we need a set for home and a set for school. We can afford it, but many parents can’t.
I don’t know how the executives at Mylan sleep at night.
★ Tuesday, 23 August 2016